Contract Research Services in Integrated Drug Discovery and Custom Radiolabelling.
A leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP certified 14C custom radiolabelling services, Selcia is a self-funded, profitable, private company with around 80 employees operating from state-of-the-art laboratories. SELCIA DISCOVERY offers integrated drug discovery services including screening biology, medicinal chemistry, ADME/PK and in vivo PK work.
Spero Oncology Ltd
Spero Oncology Ltd is an oncology company devoted to specialised research and customer-focused partnerships in the battle against cancer. Created by the core research leaders from the well known and respected Nexus Oncology, the Spero Managment team includes experienced, knowledgeable oncology experts committed to personalised service in trial managment.
Ms Theresa BruceDirector
Synpromics are a Synthetic Biology company with IP and know-how in the customized design of Synthetic Promoters.
The synthetic promoters we design enable the controlled expression of genes at a specific place, in a specific environment, at a specific time, or in response to a specific biological condition.
We provide promoter solutions to our customers across multiple fields of use, such as:
- Targeted gene therapies and DNA vaccines: we have created cell line specific promoters, such as lung, liver, keratinocytes and colorectal cancer cells.
- Enhanced functionality of cell therapies: we can create cell, biological condition and environment specific promoters.
- Biotherapeutic protein production: we have created CHO based promoters with >5X expression levels of CMV.
- Improved efficiencies in industrial bioprocesses for bio-fuel, enzyme and reagent manufacture: create inducible promoters for mammalian cells and yeast.
- Additional applications in diagnostics and as research tools.
Our clients use our promoters in their applications and products. As each promoter can be IP protected it allows opportunities for enhanced protection of product pipelines.
SYNthesis med chem
SYNthesis med chem is a global contract research organisation with world-class synthetic and medicinal chemistry capabilities. Established in 2007, SYNthesis operates a unique, “Best of Both Worlds” business model combining Western medicinal chemistry and project management expertise with high quality, cost effective and scalable synthetic chemistry based in China.
Our medicinal chemists, based in the UK (Cambridge), Australia (Melbourne) and the USA (San Francisco) provide the design, innovation, creativity and problem solving expertise required to complement the skills and capabilities of the our synthetic chemists based in Shanghai & Suzhou. Our medicinal chemists are all experienced and highly skilled scientists with a track record of delivering clinical candidates, a passion for discovering new medicines and a comprehensive insight gained from managing more than 100 projects covering all phases of the pharmaceutical R&D pipeline. They also act as project managers for all custom synthesis and medicinal chemistry projects.
SYNthesis med chem's advantages can be summarised as follows;
Chemistry focussed CRO
- we work exclusively on custom synthesis & medicinal chemistry projects
- we are experts at carrying out the synthesis of “challenging” compounds
“Best of Both Worlds” business model
- Complementarity of chemistry capabilities
- Cost effective
Flexible business model - from fee-for-service custom synthesis projects to dual contribution/dual reward shared risk collaborations
Professor Andrew WilksExecutive Chairman
Mr Simon BuryHead of Business Development
The BioHub Birmingham
exhibiting at booth 56c
New Biomedical Innovation Hub. Shared facilities (including equipment) for start-ups/SMEs and bespoke laboratory design for more established companies. Unique affordable location in Edgbaston Medical Quarter. Business support and advice also provided.
We are situated at the heart of a growing cluster which includes Birmingham Research Park, University of Birmingham Biomedical Sciences and Medical School, QE UHB Hospital, The Women's Hospital, new Institute of Translational Medicine, NHSBT, Rare Disease Centre and Welcome Trust Research facility. In addition, future expansion includes relocation of The Children's Hospital, new Dental School and Hospital, and a Life Science Campus which will provide grow-on space.
Mrs Helen Miller-VineyBusiness Development Manager
United Life Sciences (ULS)
United Life Sciences (ULS) is a strategic partnership representing 1225 life science and healthcare organisations across the UK and internationally. The partnership was formed by four Founding Partners: the BioIndustry Association (BIA), Bionow, BioPartner UK and One Nucleus (ON) in 2014 and MediWales joined in 2015.
The ULS collaboration has member and the wider UK life science sector at the heart of its purpose and is the basis for all joint activities. We strive to avoid duplication of effort and coordinate the founders' activities whilst recognising each other's areas of strength so that member companies can benefit from more effective and coherent sector support.
Since 2012 ULS partners have worked together on a range of activities - including the creation and publication of a UK Life Science Manifesto 2015 - 2020, which is aimed at all political parties, and calls for the Biomedical Catalyst scheme to be continued in the interest of the nation's health and wealth. ULS has also hosted a number of joint events both in the UK and overseas, and will be undertaking further joint initiatives plus providing cost effective attendance at each other's events to maximise the international impact of the UK.
The 1225 life science member companies are listed here:
United Life Sciences member companies